TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Participants That Were 2-level Composite Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean CLASI Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Total Wake Time After Sleep Onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Perceived Stress Scale 4 (PSS-4) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Clinician Administered PTSD Scale for DSM-5
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Atopic sensitisation measured by skin prick test (SPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lower respiratory tract infection (LRTI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Lower respiratory tract infection (LRTI) hospital admissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in child care center pesticide exposures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in personal pesticide exposures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in clinical decision-making
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: TAM Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Gut bacterial composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mucosal bacterial composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Bacterial metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Functional Knee Society Score (KSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rhythm status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cardiac hemodynamic status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Amount of soft tissue re-growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in glans size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CIA questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Identification of iron overloaded patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: sensitivity of FDG-PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: specificity of FDG-PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor evoked potential (MEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Isometric Ankle Plantar Flexion strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Fugl-Meyer assessment (FMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline WOMAC scores at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from Baseline structural outcomes scores at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mood survey scale subscales
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: HaemoglobinA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean rate of decline of ALS-FRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of somatic hypermutation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Severe oral mucositis
Endpoint domain: Adverse events/effects
Primary endpoint: Total radioactivity (TRA) concentration equivalents in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TRA concentration equivalents in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TRA concentration equivalents in feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug concentrations in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erythroid Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Marginal bone resorption measurements (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score of Atopic Dermatitis (oSCORAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Drop-out Rate Caused by Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Error-related negativity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-range temporal correlations of theta oscillations in resting EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Late positive potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probing attachment level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of major vascular complications
Endpoint domain: Adverse events/effects
Primary endpoint: Cognitive task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 hour retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Human Complement Serum Bactericidal Activity (hSBA) Titers≥ 1:8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Genetic abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose Utilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Skeletal Muscle Capillarization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Reactive Hyperemia Peripheral Arterial Tonometry (RH-PAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Base Line Oxidized Low Density Lipoprotein (LDL) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cellular populations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of hospital readmissions for heart failure
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Pharmacokinetic profile of metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assess safety
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Change in Liver Fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent Change in Liver Stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peristasis changes from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Level of Low Back Pain-associated Disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Average 7-day Self-reported Level of Low Back Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transcriptional changes in gut microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Overall Improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Spontaneous passage of stone or gravel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Appearance of new stones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: More than 30 percent increase in pre-existing stone size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Adverse clinic events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Observed Serum Concentration (Cmax) of Adalimumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Serum Concentration-Time Curve Over the Dosing Interval (AUCtau) of Adalimumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic Response of Pulmonary Lesions and Thoracic Lymph Nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Speech understanding in quiet with cochlear implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of leukocyte activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in cognitive test battery score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of successful live births
Endpoint domain: Mortality/survival
Primary endpoint: Count of Participants with Treatment-Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Total iron binding capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: transit time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean daily pain intensity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean 24 h systolic and diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibody Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: allergen concentration to induce allergic reactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of participants who develop pregnancy-induced hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of neonates who require neonatal intensive care unit admission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of participants who develop pre-eclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Ankle Hind Foot Scale (AHS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with adverse events related to the index-procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experienced a Dose Limiting Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in food challenge threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: N3 Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of Oral Analgesic Consumed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Amount of Pain Analyzed From Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Psychologic Disturbances
Endpoint domain: Adverse events/effects
Primary endpoint: Infantile Colic Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective and subjective cosmetic appearance
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Hamilton Rating Scale for Depression-24 (HRSD24)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of Satiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of insulin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plaque Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Urinary tract infection (UTI) events
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of surgical needles visible under ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: number and severity of nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: number and severity of vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in Mayo score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: Change in quadriceps force output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in voluntary activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Number of utilizable blastocysts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: DNA methylation of infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modulation of alpha power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of coronary revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: short-term outcome of the graft function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fusion at 12 months postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percent Change From Baseline in Maximum Reading Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to First Rehospitalization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Liver damage measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in ADHD scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PFDI-20 score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: oxytocin serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood pressure (mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood oxygen saturation (the fraction of oxygen)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Heart Rate (beats per minute)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Metabolic activity (glucose-uptake) in vivo, standardised uptake value (SUV) in FDG-PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Renal allograft acceptance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Ability to discontinue immunosuppressive therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained viral response 12 weeks after discontinuation of study treatment (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New grade 3 or 4 adverse event or premature study drug discontinuation due to an adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Change of Cerebral Glutathione Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corrected QT segment of ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Amount of Tobacco Product Used
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Lateral Temporal Cortex Connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in plaque scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Haemodynamic response during head up tilt test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of prodromal symptoms during head up tilt test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of syncope during head up tilt test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laboratory measurements for safety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrocardiograms (ECGs) for safety
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in pain intensity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Occurrences of dose-limiting toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Patient-Specific Functional Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rotational Stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of total constipation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Frequency of early-type constipation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Frequency of late-type constipation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of Adverse Event within 28 days post the second study intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Immunogenicity of MVC-COV1901
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postoperative functional outcomes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Risk of COVID-19 infection
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in aerobic performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of hypersensitivity events
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of seizures/convulsions events
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of lower respiratory tract infection events
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of wheezing events
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of Guillain-Barré syndrome events
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of Bell's palsy events
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of encephalitis events
Endpoint domain: Adverse events/effects
Primary endpoint: Cancer Dyspnea Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Progression of the disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of the spinal curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Overall colon cleansing efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Right colon cleansing efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduced probability of recurrent bacterial vaginosis/vaginitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Immunogenicity of DTacP-IPV//PRP~T combined vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical response of SMA patients to Nusinersen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Change in fMRI BOLD Signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Successful Placement of Peripherally Inserted Central Catheter (PICC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Muscle force and endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: N-Acetyl-Aspartate / creatine quotient in normal appearing white matter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Safety of lamotrigine in combination with interferon beta 1a
Endpoint domain: Adverse events/effects
Primary endpoint: AUC 0-t of AKB-6548
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC 0-inf of AKB-6548
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of AKB-6548
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Added Warning Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving an IGA Score of Clear or Almost Clear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Inflammatory Lesion Counts on the Face at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Non-Inflammatory Lesion Counts on the Face at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Running-related injuries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjusted Mean Endurance Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Ki67 staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Grade 3 and Higher-grade Treatment-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Humoral immunity to varicella zoster
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes